3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Stomach Neoplasms
2
Lung Neoplasms
2
Sarcoma
1
Recurrence
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Advanced Non-Small Cell Lung Cancer
1
Advanced Non Small Cell Lung Cancer
1
Acrocephalosyndactylia
1
Interventions
Docetaxel
8
pembrolizumab
7
Pemetrexed
5
Carboplatin
5
Erlotinib Hydrochloride
4
toripalimab
3
rociletinib
3
fludarabine
3
Radiosurgery
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Gemcitabine
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Bevacizumab
3
lorlatinib
2
atezolizumab
2
Vinorelbine
2
Topotecan
2
Radiotherapy
2
Platinum
2
Itraconazole
2
Irinotecan
2
Interleukin-2
2
Cetuximab
2
Albumin-Bound Paclitaxel
2
vinflunine
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
pemigatinib
×
Thoracic
×
Clear all
NCT05253807
2025-08-05
FIGHT-210
Incyte Corporation
Phase 2
Completed
8 enrolled
13 charts